logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation

Liaoning Port (02880): Xu Song resigns as non-executive director.

date
17:53 07/09/2023
avatar
GMT Eight
Liaoning Port (02880) has announced that Mr. Xu Song has resigned as a non-executive director effective from September 6, 2023, due to a job change. Additionally, Dr. Xu will no longer serve as a member of the Board's Strategic Development Committee.
Related Articles
HK Stock Market Move | VOBILE GROUP (03738) rose nearly 6% in the afternoon. Cumulative registered users of the SeeBay platform have exceeded 20,000 four days after its launch.
HK Stock Market Move | ALEBUND-B(09637) Surges Over 8% as FDA Approves New Drug Application for AP308 in Treating IgAN, with Therapeutic Potential Already Validated in the Field of Renal Medicine
Morningstar: First coverage of CHOW TAI FOOK (01929) with fair value of HK$14.5 per share.
HK Stock Market Move | VOBILE GROUP (03738) rose nearly 6% in the afternoon. Cumulative registered users of the SeeBay platform have exceeded 20,000 four days after its launch.
HK Stock Market Move | ALEBUND-B(09637) Surges Over 8% as FDA Approves New Drug Application for AP308 in Treating IgAN, with Therapeutic Potential Already Validated in the Field of Renal Medicine
Morningstar: First coverage of CHOW TAI FOOK (01929) with fair value of HK$14.5 per share.
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.